MCT 101
Alternative Names: MCT-101Latest Information Update: 26 Apr 2023
At a glance
- Originator University of Minnesota
- Developer Finch Therapeutics Group; University of Minnesota
- Class Anti-inflammatories; Antineoplastics; Bacteria; Behavioural disorder therapies; Probiotics
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Acute myeloid leukaemia; Non-small cell lung cancer; Pervasive child development disorders
Most Recent Events
- 22 Nov 2022 Phase-II clinical trials in Non-small cell lung cancer (First-line therapy, Metastatic disease, Late-stage disease; Combination therapy) in USA (PO) (NCT04105270)
- 28 Jan 2022 Finch Therapeutics in-licenses formulations comprising human fecal microbes, methods of increasing microbiota diversity, and methods of decreasing the relative abundance of certain bacteria from University of Minnesota
- 15 Nov 2019 Phase-II clinical trials in Pervasive child development disorders (In children, In adolescents) in USA (PO) (NCT04182633)